INSURE: a pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed/refractory myeloma in routine practice.

IF 3 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2024-05-01 Epub Date: 2024-01-10 DOI:10.2217/fon-2023-0604

Xavier Leleu, Hans C Lee, Jeffrey A Zonder, Margaret Macro, Karthik Ramasamy, Cyrille Hulin, Jiri Silar, Matyas Kuhn, Kaili Ren, Nawal Bent-Ennakhil, Dasha Cherepanov, Dawn Marie Stull, Evangelos Terpos

{"title":"INSURE: a pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed/refractory myeloma in routine practice.","authors":"Xavier Leleu, Hans C Lee, Jeffrey A Zonder, Margaret Macro, Karthik Ramasamy, Cyrille Hulin, Jiri Silar, Matyas Kuhn, Kaili Ren, Nawal Bent-Ennakhil, Dasha Cherepanov, Dawn Marie Stull, Evangelos Terpos","doi":"10.2217/fon-2023-0604","DOIUrl":null,"url":null,"abstract":"Aim: We pooled data from three observational studies (INSIGHT MM, UVEA-IXA and REMIX) to investigate the real-world effectiveness of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory myeloma. Materials & methods: INSIGHT MM was a prospective study conducted in countries across Europe, Asia and North/Latin America while UVEA-IXA and REMIX were multicenter, retrospective/prospective studies conducted in Europe. Patients who had received IRd as ≥2nd line of therapy were analyzed. Primary outcomes were time-to-next treatment (TTNT) and progression-free survival (PFS). Results: Overall, 564 patients were included (median follow-up: 18.5 months). Median TTNT and PFS were 18.4 and 19.9 months; both outcomes were numerically longer for earlier versus later lines. Median treatment duration was 14.0 months. Overall response rate was 64.6%. No new safety concerns were noted. Conclusion: The effectiveness of IRd in routine practice appears similar to the efficacy observed in TOURMALINE-MM1. IRd benefit in earlier versus later lines was consistent with previous reports.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"935-950"},"PeriodicalIF":3.0000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/fon-2023-0604","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/10 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: We pooled data from three observational studies (INSIGHT MM, UVEA-IXA and REMIX) to investigate the real-world effectiveness of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory myeloma. Materials & methods: INSIGHT MM was a prospective study conducted in countries across Europe, Asia and North/Latin America while UVEA-IXA and REMIX were multicenter, retrospective/prospective studies conducted in Europe. Patients who had received IRd as ≥2nd line of therapy were analyzed. Primary outcomes were time-to-next treatment (TTNT) and progression-free survival (PFS). Results: Overall, 564 patients were included (median follow-up: 18.5 months). Median TTNT and PFS were 18.4 and 19.9 months; both outcomes were numerically longer for earlier versus later lines. Median treatment duration was 14.0 months. Overall response rate was 64.6%. No new safety concerns were noted. Conclusion: The effectiveness of IRd in routine practice appears similar to the efficacy observed in TOURMALINE-MM1. IRd benefit in earlier versus later lines was consistent with previous reports.

查看原文本刊更多论文

INSURE：伊沙佐米-来那度胺-地塞米松治疗复发/难治性骨髓瘤的常规疗法汇总分析。

目的：我们汇总了三项观察性研究（INSIGHT MM、UVEA-IXA 和 REMIX）的数据，以调查伊沙佐米-来那度胺-地塞米松（IRd）在复发/难治性骨髓瘤中的实际疗效。材料与方法：INSIGHT MM是一项前瞻性研究，在欧洲、亚洲和北美洲/拉丁美洲各国开展，而UVEA-IXA和REMIX则是在欧洲开展的多中心、回顾性/前瞻性研究。研究分析了接受 IRd 作为≥二线疗法的患者。主要结果是下次治疗时间（TTNT）和无进展生存期（PFS）。结果：共纳入 564 例患者（中位随访时间：18.5 个月）。TTNT和PFS的中位数分别为18.4个月和19.9个月；这两项结果在数量上都是前线患者长于后线患者。中位治疗时间为 14.0 个月。总体反应率为 64.6%。未发现新的安全性问题。结论IRd在常规治疗中的疗效与在TOURMALINE-MM1中观察到的疗效相似。IRd在早产线与晚产线中的获益与之前的报告一致。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.